2. Academic Validation
  3. Discovery of novel benzylaniline derivatives containing chloroacetamide as GPX4 inhibitors with potential efficacy in triple-negative breast cancer

Discovery of novel benzylaniline derivatives containing chloroacetamide as GPX4 inhibitors with potential efficacy in triple-negative breast cancer

  • Eur J Med Chem. 2025 Dec 15:300:118189. doi: 10.1016/j.ejmech.2025.118189.
Mengdan Ning 1,  Bo Zhao 1,  Tianjie Cao 1,  Jiaxing Wu 1,  Chao Zhang 1,  Lingyi Kong 2,  Jianguang Luo 3,  Yong Yin 4
Affiliations

Affiliations

  • 1 Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Basic Medical Research Innovation Center for Anti-Cancer Drugs (MOE), School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
  • 2 Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Basic Medical Research Innovation Center for Anti-Cancer Drugs (MOE), School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. Electronic address: cpu_lykong@126.com.
  • 3 Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Basic Medical Research Innovation Center for Anti-Cancer Drugs (MOE), School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. Electronic address: luojg@cpu.edu.cn.
  • 4 Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Basic Medical Research Innovation Center for Anti-Cancer Drugs (MOE), School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. Electronic address: yongyin@cpu.edu.cn.
PMID: 40986987 DOI: 10.1016/j.ejmech.2025.118189
Abstract

Studies have found that induction of Ferroptosis in tumors may become a new treatment method. Glutathione Peroxidase 4 (GPX4) has become a promising target for Cancer treatment by inducing Ferroptosis, of which covalent GPX4 inhibitors are the most widely studied class so far. A series of GPX4 inhibitors containing chloroacetyl warheads were designed and synthesized, and the antiproliferative activity was evaluated using six tumor cell lines. Among them, compound Y19 showed strong anti-proliferative activity with high Ferroptosis selectivity against MDA-MB-231 cells with IC50 value of 21 nM. Moreover, Y19 effectively inhibited GPX4 activity and molecular docking revealed that Y19 may covalently bind to Sec 46 site of GPX4. In addition, compound Y19 caused intracellular Fe2+ accumulation, leading to increased levels of lipid peroxides (LPOs) and induction of Ferroptosis. This was followed by the discovery that Y19 induced Ferroptosis by LPOs and Reactive Oxygen Species (ROS) production leading to DNA damage. In vivo pharmacodynamic evaluation demonstrated that Y19 exhibited superior antitumor efficacy compared to RSL3 at an equivalent dose, achieving a tumor growth inhibition (TGI) rate of 72.53 % at 10 mg/kg in the MDA-MB-231 xenograft model, with no significant toxicity observed. This provides structurally diverse tool compounds to reveal the basic biology of GPX4 as well as to explore potential efficacy with the treatment of Cancer by inducing Ferroptosis.

Keywords

Covalent inhibitors; Ferroptosis; Glutathione peroxidase 4; Lipid peroxidation.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z